Department of Microbiology, Infectiology and Immunology, Infectious Disease Research Center, Laval University, 2705 boulevard Laurier, Quebec City, QC G1V 4G2, Canada.
Neurosciences, Laval University, 2705 boulevard Laurier, Québec City, QC G1V 4G2, Canada.
Nanomedicine. 2022 Aug;44:102584. doi: 10.1016/j.nano.2022.102584. Epub 2022 Jul 16.
A vaccine candidate to SARS-CoV-2 was constructed by coupling the viral receptor binding domain (RBD) to the surface of the papaya mosaic virus (PapMV) nanoparticle (nano) to generate the RBD-PapMV vaccine. Immunization of mice with the coupled RBD-PapMV vaccine enhanced the antibody titers and the T-cell mediated immune response directed to the RBD antigen as compared to immunization with the non-coupled vaccine formulation (RBD + PapMV nano). Anti-RBD antibodies, generated in vaccinated animals, neutralized SARS-CoV-2 infection in vitro against the ancestral, Delta and the Omicron variants. At last, immunization of mice susceptible to the infection by SARS-CoV-2 (K18-hACE2 transgenic mice) with the RBD-PapMV vaccine induced protection to the ancestral SARS-CoV-2 infectious challenge. The induction of the broad neutralization against SARS-CoV-2 variants induced by the RBD-PapMV vaccine demonstrate the potential of the PapMV vaccine platform in the development of efficient vaccines against viral respiratory infections.
一种针对 SARS-CoV-2 的疫苗候选物是通过将病毒受体结合域（RBD）与木瓜花叶病毒（PapMV）纳米颗粒（nano）的表面偶联来构建的，从而生成 RBD-PapMV 疫苗。与非偶联疫苗制剂（RBD+PapMV nano）相比，用偶联的 RBD-PapMV 疫苗免疫小鼠增强了针对 RBD 抗原的抗体滴度和 T 细胞介导的免疫反应。在接种疫苗的动物中产生的抗 RBD 抗体，在体外中和了针对原始、Delta 和奥密克戎变体的 SARS-CoV-2 感染。最后，用 RBD-PapMV 疫苗免疫易感染 SARS-CoV-2 的小鼠（K18-hACE2 转基因小鼠），诱导对原始 SARS-CoV-2 感染性挑战的保护。RBD-PapMV 疫苗诱导的针对 SARS-CoV-2 变体的广泛中和反应表明，PapMV 疫苗平台在开发针对病毒性呼吸道感染的有效疫苗方面具有潜力。
